標(biāo)題: Titlebook: Cancer Drug Resistance; Methods and Protocol Marta Baiocchi Book 2022 The Editor(s) (if applicable) and The Author(s), under exclusive lice [打印本頁] 作者: 巡洋 時(shí)間: 2025-3-21 16:52
書目名稱Cancer Drug Resistance影響因子(影響力)
書目名稱Cancer Drug Resistance影響因子(影響力)學(xué)科排名
書目名稱Cancer Drug Resistance網(wǎng)絡(luò)公開度
書目名稱Cancer Drug Resistance網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Cancer Drug Resistance被引頻次
書目名稱Cancer Drug Resistance被引頻次學(xué)科排名
書目名稱Cancer Drug Resistance年度引用
書目名稱Cancer Drug Resistance年度引用學(xué)科排名
書目名稱Cancer Drug Resistance讀者反饋
書目名稱Cancer Drug Resistance讀者反饋學(xué)科排名
作者: BRIEF 時(shí)間: 2025-3-21 23:09
Patient-Derived Breast Cancer Tissue Cultures for Anti-Endocrine Drug Assays,t cancers express the estrogen receptor alpha (ER), which plays a pivotal role in the pathobiology of the disease and are therefore classified as ER-positive (ER.). In fact, targeting of the ER signaling pathway is the main therapeutic strategy for ER. breast cancer. Despite the success of endocrine作者: Immobilize 時(shí)間: 2025-3-22 01:14 作者: 誤傳 時(shí)間: 2025-3-22 06:19 作者: 詞匯記憶方法 時(shí)間: 2025-3-22 11:24 作者: 雪上輕舟飛過 時(shí)間: 2025-3-22 16:31 作者: 雪上輕舟飛過 時(shí)間: 2025-3-22 20:22
A Label Retaining System to Capture Slow-Cycling Cancer Cells, adjuvant therapy. Slow-cycling cancer cells (SCCC) represent a cellular status rather than a cell population present in a minor proportion, even in growing tumors. We have adapted the pulse-chase expression of histone H2B fused to enhanced GFP (H2BeGFP) for labelling and isolating SCCC. SCCC show c作者: Awning 時(shí)間: 2025-3-22 23:32
A Fast and Furious Liquid Biopsy Assay to Monitor Targeted Therapy Resistance,e manner. Of the various circulating biomarkers available for liquid biopsy, circulating tumor cells (CTC)?and circulating tumor DNA (ctDNA)?are the most intensively studied to date. However, CTC and ctDNA represent different tumor components, therefore, complementary information from both sources m作者: Derogate 時(shí)間: 2025-3-23 03:49
Assessment of Tumor Heterogeneity in High-Grade Serous Ovarian Cancer: Mass Cytometry to Understandmotherapy; however, despite recent development of new therapeutic approaches based on combination of chemotherapy and innovative targeted-therapies, most of them relapse due to chemoresistance. Many studies have been carried out to decipher the high heterogeneity of ovarian cancer cells that drives 作者: Melanoma 時(shí)間: 2025-3-23 08:01 作者: 驚惶 時(shí)間: 2025-3-23 10:46
Simultaneous Mapping of Enhancers and Enhancer Rearrangements with Paired-End H3K27ac ChIP-seq, map enhancers and their activity and to identify structural variations at enhancers. Since changes in enhancer activity and new enhancer translocations both play a major role in tumor initiation, progression, and response to therapy, this approach holds promise to uncover some of the mechanisms beh作者: CRACY 時(shí)間: 2025-3-23 15:54 作者: 使混合 時(shí)間: 2025-3-23 18:21
RNA Sequencing Data Analysis on the Maser Platform and the Tag-Count Comparison Graphical User Inteof RNA-seq output data are indispensable for research, but bioinformatics experts are not always available to assist. Currently, however, even a wet-lab specialist can perform the pipeline analysis of RNA-seq described in this chapter using the Maser platform and the Tag-Count Comparison Graphical U作者: enumaerate 時(shí)間: 2025-3-24 01:27 作者: essential-fats 時(shí)間: 2025-3-24 03:07
Polygenomic Interrogation of Drug Resistance Genes,otherapy. Pharmacogenomic methods seek to understand the interaction of genomic variation and response to chemotherapeutic treatment. This chapter presents a workflow to interrogate multiple genomic inputs and individually assess their relationship with the phenotype of drug resistance using hierarc作者: arsenal 時(shí)間: 2025-3-24 09:25
Analysis of ER-Phagy in Cancer Drug Resistance,o develop resistance to chemotherapies. Autophagy and more specifically organelle specific autophagy is one such adaptive mechanism that promotes drug resistance in cancer cells. Endoplasmic reticulum–specific autophagy or ER-phagy has been more recently described to overcome ER-stress through the d作者: 預(yù)兆好 時(shí)間: 2025-3-24 11:29 作者: 安定 時(shí)間: 2025-3-24 15:41 作者: assail 時(shí)間: 2025-3-24 20:38
https://doi.org/10.1007/978-94-009-7043-4facile visualization of cells with light microscopy and the ability to add (or subtract) drugs or biomolecules to interrogate the system or modulate the cellular response. Finally, the approach allows for terminal immunostaining of either (or both) cell types.作者: indifferent 時(shí)間: 2025-3-25 01:18 作者: INTER 時(shí)間: 2025-3-25 06:36
https://doi.org/10.1007/978-94-009-8567-4linical relapsed tumors (Yogev et al. Cancer Res. 79:5382–5393, 2019). We believe that this protocol can be used to generate faithful models for other types of relapse disease; these could serve as reliable tools while developing novel therapies.作者: 時(shí)代 時(shí)間: 2025-3-25 08:22
https://doi.org/10.1007/978-3-540-87866-7 cuts DNA in regions that are open and therefore accessible for transcription factors, regulatory RNAs and proteins that alter the architectural structure of the DNA and drive or inhibit transcription through the RNA polymerase. Here we describe a detailed protocol to perform an ATAC-seq of cells from culture or tissue.作者: 單純 時(shí)間: 2025-3-25 14:04 作者: exhibit 時(shí)間: 2025-3-25 18:07
https://doi.org/10.1007/978-3-540-87866-7ld play a critical role in the development of drug resistance in cancer cells. Therefore, here, we provide a lay description of how ER-phagy could be investigated biochemically by Western blot analysis and silencing ER-phagy receptor genes using small interfering RNAs (siRNA).作者: 不遵守 時(shí)間: 2025-3-25 23:56 作者: Atrium 時(shí)間: 2025-3-26 01:52
A Methodological Workflow to Analyze Synthetic Lethality and Drug Synergism in Cancer Cells,resistance. Mechanisms of drug resistance in cancers are manifold but critical to assess, in view of restoring drug sensibility. In this chapter, we provide a framework to investigate synthetic lethality and synergistic interactions, as well as drug resistance in cancer cells in vitro.作者: 軟膏 時(shí)間: 2025-3-26 04:55
Establishment of In Vivo Acquired Resistance to Chemotherapy Via Individual Dose Escalation Treatmelinical relapsed tumors (Yogev et al. Cancer Res. 79:5382–5393, 2019). We believe that this protocol can be used to generate faithful models for other types of relapse disease; these could serve as reliable tools while developing novel therapies.作者: 無法破譯 時(shí)間: 2025-3-26 09:55 作者: 魅力 時(shí)間: 2025-3-26 14:59
Polygenomic Interrogation of Drug Resistance Genes,the mechanism underlying resistance. In this chapter, we describe a computational method that can be adapted to a number of different diseases and phenotypes in which there are multiple genomic data types available with concordant phenotypic drug resistance information.作者: Barter 時(shí)間: 2025-3-26 17:29
Analysis of ER-Phagy in Cancer Drug Resistance,ld play a critical role in the development of drug resistance in cancer cells. Therefore, here, we provide a lay description of how ER-phagy could be investigated biochemically by Western blot analysis and silencing ER-phagy receptor genes using small interfering RNAs (siRNA).作者: 使害羞 時(shí)間: 2025-3-26 22:29 作者: Evolve 時(shí)間: 2025-3-27 01:28 作者: Ataxia 時(shí)間: 2025-3-27 07:45 作者: anthesis 時(shí)間: 2025-3-27 11:28
Neutron Radiography at Lucas Heightsel of BC through the generation and ex vivo culture of patient-derived organotypic tumor spheroids (PDOTS) in a 3D microfluidic device. Moreover, the real-time screening of conventional chemotherapy agents on cultured PDOTS is also described.作者: Granular 時(shí)間: 2025-3-27 13:39
https://doi.org/10.1007/978-3-540-87866-7ab specialist can perform the pipeline analysis of RNA-seq described in this chapter using the Maser platform and the Tag-Count Comparison Graphical User Interface (TCC-GUI). These are free of charge for scientific use.作者: 過時(shí) 時(shí)間: 2025-3-27 20:06
A 3D Biomimetic System for Testing Anticancer Drug Sensitivity,ce (MDR) mechanisms. This 3D culture model resembles in vivo conditions and provides relevant and reproducible results. It is easy to set up and allows for facile manipulation for downstream analyses. All these remarkable features make this 3D culture model a promising tool in drug discovery and cancer cell biology research.作者: 突變 時(shí)間: 2025-3-27 22:00
Generation and Culture of Organotypic Breast Carcinoma Spheroids for the Study of Drug Response in el of BC through the generation and ex vivo culture of patient-derived organotypic tumor spheroids (PDOTS) in a 3D microfluidic device. Moreover, the real-time screening of conventional chemotherapy agents on cultured PDOTS is also described.作者: Incumbent 時(shí)間: 2025-3-28 03:06 作者: 倒轉(zhuǎn) 時(shí)間: 2025-3-28 08:37
https://doi.org/10.1007/978-3-540-87866-7ancer-initiation potential and enhanced chemoresistance, and present a distinctive nongenetic and cell-autonomous gene expression profile shared across different tumor types. The use of our H2BeGFP pulse-chase method opens the possibility to study live SCCC in any growing tissue either cancerous or normal.作者: Epidural-Space 時(shí)間: 2025-3-28 13:33
https://doi.org/10.1007/978-3-540-87866-7ight be beneficial. This protocol focuses on the description of a sample processing workflow that allowed for concurrent isolation of CTC and ctDNA from the same source sample. This single tube approach enables simultaneous analysis of multiple biomarkers to better monitor cancer drug resistance.作者: 豪華 時(shí)間: 2025-3-28 16:04 作者: 詞匯記憶方法 時(shí)間: 2025-3-28 21:09 作者: ironic 時(shí)間: 2025-3-28 23:23 作者: 逗它小傻瓜 時(shí)間: 2025-3-29 03:10 作者: Ige326 時(shí)間: 2025-3-29 07:15 作者: Evolve 時(shí)間: 2025-3-29 12:25
Identification of Drug Resistance Mechanisms Using Genome-Wide CRISPR-Cas9 Screens,ene-drug interactions. Here, we outline a protocol for performing positive and negative selection genome-wide CRISPR-Cas9 screens for identifying gene knockouts that cause drug resistance and hypersensitivity. This protocol is designed for the use of the TKOv3 library in human cell lines, but can be readily adapted for different libraries.作者: 痛恨 時(shí)間: 2025-3-29 16:26 作者: Delude 時(shí)間: 2025-3-29 23:12 作者: Exterior 時(shí)間: 2025-3-30 01:10
https://doi.org/10.1007/978-1-0716-2513-2Drug resistant cells; Drug design and targeting; Early detection; Molecular analysis; Determinants of re作者: 長矛 時(shí)間: 2025-3-30 06:50
978-1-0716-2515-6The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Science+Busines作者: humectant 時(shí)間: 2025-3-30 10:52
Simultaneous Mapping of Enhancers and Enhancer Rearrangements with Paired-End H3K27ac ChIP-seq, map enhancers and their activity and to identify structural variations at enhancers. Since changes in enhancer activity and new enhancer translocations both play a major role in tumor initiation, progression, and response to therapy, this approach holds promise to uncover some of the mechanisms behind these processes.作者: 裂口 時(shí)間: 2025-3-30 14:32
Drug Target Prediction Using Context-Specific Metabolic Models Reconstructed from rFASTCORMICS,er but also to predict drug targets and candidate drugs for repurposing. Here, we will elaborate on the reconstruction of context-specific metabolic models of cancer using rFASTCORMICS and the subsequent prediction of drugs for repurposing using our drug prediction workflow.作者: ALE 時(shí)間: 2025-3-30 18:24 作者: 無脊椎 時(shí)間: 2025-3-30 21:48 作者: 自由職業(yè)者 時(shí)間: 2025-3-31 01:25
https://doi.org/10.1007/978-94-009-7043-4ically separate, yet chemically connect, two cell types; however, the majority of these approaches utilize batch culture conditions which can result in nutrient depletion and waste accumulation. This chapter describes an alternative approach that allows for the continuous infusion of media, relievin作者: Magnificent 時(shí)間: 2025-3-31 06:59 作者: 阻礙 時(shí)間: 2025-3-31 12:25
Neutron Radiography at Lucas Heightss-all” therapeutic concept may commonly fail in terms of efficacy, evolving drug resistance, and side effects. In times of omics, novel elaborated and personalized approaches emerge for efficiently eradicate cancer cells, while sparing healthy cells. Synthetic lethality-based strategies offer promis作者: 放肆的你 時(shí)間: 2025-3-31 13:54
https://doi.org/10.1007/978-94-009-8567-4lapsed disease hinders the development of novel therapeutics. 2D and 3D in vitro cell-based assays have provided some information, but this is limited and does not consider the role of the tumor microenvironment. The development of an in vivo assay can allow to generate resistance, while taking into
